Georgia's Online Cancer Information Center

Find A Clinical Trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06297226
Protocol IDs
CA088-1000 (primary)
NCI-2024-02712
Study Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Summary

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene
Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Eligibility

  1. Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
  2. Received at least 3 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, and at least 3 prior lines of therapy (LOT).
  3. Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
  4. Participants must have measurable disease during screening.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)


1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523


**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.